Novel strategy for treatment of pulmonary arterial hypertension: Enhancement of apoptosis

Lung

Volumn 188, Issue 3, 2010, Pages 179-189

  Huang, Jing Bin ^a   Liu, Ying Long ^a   Sun, Pei Wu ^b   Lv, Xiao Dong ^a   Bo, Kong ^a   Fan, Xiang Ming ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Apoptosis; PASMC; Pulmonary vascular remodeling

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; APOPTOSIS SIGNAL REGULATING KINASE 1; B 9972; BCL2 RELATED PROTEIN A1; BRADYKININ RECEPTOR; BRADYKININ RECEPTOR AGONIST; CALCIUM ANTAGONIST; CALCIUM ION; CASPASE; COMPACTIN; DICHLOROACETIC ACID; ELASTASE; ELASTASE INHIBITOR; FASUDIL; NUCLEASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; POTASSIUM CHANNEL; POTASSIUM ION; PROTEIN BAX; RHO KINASE; RHO KINASE INHIBITOR; ROSIGLITAZONE; SIMVASTATIN; SURVIVIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASODILATOR AGENT; VOLTAGE GATED CALCIUM CHANNEL; VOLTAGE GATED POTASSIUM CHANNEL;

AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; APOPTOSIS; BLOOD VESSEL WALL; CARDIOVASCULAR RISK; CELL HYPERPLASIA; CELL PROLIFERATION; CELL SURVIVAL; CELL VOLUME; CONSTIPATION; DRUG TARGETING; ENDOTHELIUM CELL; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; EXPERIMENTAL RAT; FEVER; FRACTURE; GASTROINTESTINAL SYMPTOM; HAND TREMOR; HEADACHE; HEART FAILURE; HEART PROTECTION; HUMAN; INHIBITION KINETICS; INSOMNIA; LETHARGY; LIVER DYSFUNCTION; LUNG BLOOD VESSEL; MEMBRANE DEPOLARIZATION; MUSCLE RIGIDITY; MYALGIA; MYOSITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERIPHERAL NEUROPATHY; PLEIOTROPY; POTASSIUM CURRENT; PRIORITY JOURNAL; PROTEIN DEFECT; PULMONARY ARTERIAL SMOOTH MUSCLE CELL; PULMONARY ARTERY; PULMONARY HYPERTENSION; PULMONARY VASCULAR REMODELING; RABBIT; RASH; RETINA MACULA EDEMA; REVIEW; SARCOPLASMIC RETICULUM; SIDE EFFECT; SMOOTH MUSCLE FIBER; SOMNOLENCE; SUGAR BLOOD LEVEL; SWINE; TISSUE REPAIR; TRIACYLGLYCEROL BLOOD LEVEL; URINARY OCCULT BLOOD; VASOCONSTRICTION;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; DICHLOROACETATE; HUMANS; HYPERTENSION, PULMONARY; LUNG; MICE; MUSCLE, SMOOTH, VASCULAR; PANCREATIC ELASTASE; POTASSIUM CHANNELS; PROTO-ONCOGENE PROTEINS C-BCL-2; PULMONARY ARTERY; RATS; RHO-ASSOCIATED KINASES; VASODILATOR AGENTS;

EID: 77954459259     PISSN: 03412040     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00408-010-9233-8     Document Type: Review

References (98)

1. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, BrundageBH, Detre KM, Fishman AP, Goldring RM, Groves BM, KernisJT et al (1991) Survival in patients with primary PAH: resultsfrom a national prospective registry. Ann Intern Med 115:343-349
2. Chan SY, Loscalzo J (2008) Pathogenic mechanisms of pulmonaryarterial hypertension. J Mol Cell Cardiol 44:14-30
3. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLeanMR, Lang IM, Christman BW, Weir EK, Eickelberg O, VoelkelNF, RabinovitchM(2004) Cellular and molecular pathobiology ofpulmonary arterial hypertension. J Am Coll Cardiol 43:13S-24S
4. Mandegar M, Fung YC, Huang W, Remillard CV, Rubin LJ,Yuan JX (2004) Cellular and molecular mechanisms of pulmonaryvascular remodeling: role in the development of PAH.Microvasc Res 68:75-103
5. Haunstetter A, Izumo S (1998) Apoptosis: basic mechanisms andimplications for cardiovascular disease. Circ Res 82:1111-1129
6. Thornberry NA, Lazebnik Y (1998) Caspases: enemies within.Science 281:1312-1316
7. Vu CC, Bortner CD, Cidlowski JA (2001) Differential involvementof initiator caspases in apoptotic volume decrease andpotassium efflux during Fas- and UV-induced cell death. J BiolChem 276:37602-37611
8. Gustafsson AB, Gottlieb RA (2007) Bcl-2 family members andapoptosis, taken to heart. Am J Physiol Cell Physiol 292:C45-C51
9. Gulbins E, Jekle A, Ferlinz K, Grassmé H, Lang F (2000)Physiology of apoptosis. Am J Physiol Renal Physiol 279:F605-F615
10. Remillard CV, Yuan JXJ (2004) Activation of Kt channels: anessential pathway in programmed cell death. Am J Physiol LungCell Mol Physiol 286:L49-L67
11. Green DR, Reed JC (1998) Mitochondria and apoptosis. Science281:1309-1312
12. Duchen MR (1999) Contributions of mitochondria to animalphysiology: from homeostatic sensor to calcium signalling andcell death. J Physiol 516:1-17
13. Kroemer G, Dallaporta B, Resche-Rigon M (1998) The mitochondrialdeath/ life regulator in apoptosis and necrosis. AnnuRev Physiol 60:619-642
14. Shimizu S, Ide T, Yanagida T, Tsujimoto Y (2000) Electrophysiologicalstudy of a novel large pore formed by Bax and thevoltage-dependent anion channel that is permeable to cytochromec. J Biol Chem 275:12321-12325
15. Vander Heiden MG, Chandel NS, Schumacker PT, ThompsonCB (1999) Bcl-xL prevents cell death following growth factorwithdrawal by facilitating mitochondrial ATP/ADP exchange.Mol Cell 3:159-167
16. Zamzami N, Marzo I, Susin SA, Brenner C, Larochette N,Marchetti P, Reed J, Kofler R, Kroemer G (1998) The thiolcrosslinking agent diamide overcomes the apoptosis-inhibitoryeffect of Bcl-2 by enforcing mitochondrial permeability transition.Oncogene 16:1055-1063
17. Ekhterae D, Platoshyn O, Krick S, Yu Y, McDaniel SS, Yuan JX(2001) Bcl-2 decreases voltage-gated K ? channel activity andenhances survival in vascular smooth muscle cells. Am J PhysiolCell Physiol 281:C157-C165
18. Burg ED, Remillard CV, Yuan JX (2008) Potassium channels inthe regulation of pulmonary artery smooth muscle cell proliferationand apoptosis: pharmacotherapeutic implications. Br JPharmacol 153(Suppl 1):S99-S111
19. Bonnet S, Rochefort G, Sutendra G, Archer SL, Haromy A,Webster L, Hashimoto K, Bonnet SN, Michelakis ED (2007) Thenuclear factor of activated T cells in pulmonary arterial hypertensioncan be therapeutically targeted. Proc Natl Acad Sci USA104:11418-11423
20. Yuan XJ, Wang J, Juhaszova M, Gaine SP, Rubin LJ (1998)Attenuated K? channel gene transcription in primary PAH.Lancet 351:726-727
21. Guignabert C, Izikki M, Tu LI, Li Z, Zadigue P, Barlier-Mur AM,Hanoun N, Rodman D, Hamon M, Adnot S, Eddahibi S (2006)Transgenic mice overexpressing the 5-hydroxytryptamine transportergene in smooth muscle develop PAH. Circ Res 98:1323-1330
22. Pozeg ZI, Michelakis ED, McMurtry MS, Thébaud B, Wu XC,Dyck JR, Hashimoto K, Wang S, Moudgil R, Harry G, SultanianR, Koshal A, Archer SL (2003) In vivo gene transfer of the O2-sensitive potassium channel Kv1.5 reduces PAH and restoreshypoxic pulmonary vasoconstriction in chronically hypoxic rats.Circulation 107:2037-2044
23. Bonnet S, Michelakis ED, Porter CJ, Andrade-Navarro MA,Thébaud B, Bonnet S, Haromy A, Harry G, Moudgil R,McMurtry MS, Weir EK, Archer SL (2006) An abnormal mitochondrial-hypoxia inducible factor-1alpha-Kv channel pathwaydisrupts oxygen sensing and triggers pulmonary arterial hypertensionin fawn hooded rats: similarities to human pulmonaryarterial hypertension. Circulation 113:2630-2641
24. McMurtry MS, Archer SL, Altieri DC, Bonnet S, Haromy A,Harry G, Bonnet S, Puttagunta L, Michelakis ED (2005) Genetherapy targeting survivin selectively induces pulmonary vascularapoptosis and reverses pulmonary arterial hypertension. J ClinInvest 115:1479-1491
25. Chen LB (1988) Mitochondrial membrane potential in livingcells. Annu Rev Cell Biol 4:155-181
26. Heerdt BG, Houston MA, Augenlicht LH (2005) The intrinsicmitochondrial membrane potential of colonic carcinoma cells islinked to the probability of tumor progression. Cancer Res65:9861-9867
27. Shimizu S, Eguchi Y, Kamiike W, Funahashi Y, Mignon A,Lacronique V, Matsuda H, Tsujimoto Y (1998) Bcl-2 preventsapoptotic mitochondrial dysfunction by regulating proton flux.Proc Natl Acad Sci USA 95:1455-1459
28. Geraci MW, Moore M, Gesell T, Yeager ME, Alger L, Golpon H,Gao B, Loyd JE, Tuder RM, Voelkel NF (2001) Gene expressionpatterns in the lungs of patients with primary PAH: a genemicroarray analysis. Circ Res 88:555-562
29. Platoshyn O, Golovina VA, Bailey CL, Limsuwan A, Krick S,Juhaszova M, Seiden JE, Rubin LJ, Yuan JX (2000) Sustainedmembrane depolarization and pulmonary artery smooth musclecell proliferation. Am J Physiol Cell Physiol 279:C1540-C1549
30. Yuan JX, Rubin LJ et al (2001) Pathophysiology of PAH. In:Scharf SM (ed) Respiratory-circulatory interactions in health anddisease. Marcel Dekker, New York, pp 447-477
31. Hardingham GE, Chawla S, Johnson CM, Bading H (1997)Distinct functions of nuclear and cytoplasmic calcium in thecontrol of gene expression. Nature 385:260-265
32. Golovina VA, Platoshyn O, Bailey CL, Wang J, Limsuwan A,Sweeney M, Rubin LJ, Yuan JX (2001) Upregulated TRP andenhanced capacitative Ca2 ? entry in human pulmonary arterymyocytes during proliferation. Am J Physiol Heart Circ Physiol280:H746-H755
33. Michiels C, Minet E, Michel G, Mottet D, Piret JP, Raes M(2001) HIF-1 and AP-1 cooperate to increase gene expression inhypoxia: role of MAP kinases. IUBMB Life 52:49-53
34. Zhang X, Wrzeszczynska MH, Horvath CM, Darnell JE Jr (1999)Interacting regions in Stat3 and c-Jun that participate in cooperativetranscriptional activation. Mol Cell Biol 19:7138-7146
35. Rabinovitch M (1998) Elastase and the pathobiology of unexplainedPAH. Chest 114:213S-224S
36. Zhang S, Fantozzi I, Tigno DD, Yi ES, Platoshyn O, ThistlethwaitePA, Kriett JM, Yung G, Rubin LJ, Yuan JX (2003) Bonemorphogenetic proteins induce apoptosis in human pulmonaryvascular smooth muscle cells. Am J Physiol Lung Cell MolPhysiol 285:L740-L754
37. Maeno E, Ishizaki Y, Kanaseki T, Hazama A, Okada Y (2000)Normotonic cell shrinkage because of disordered volume regulationis an early prerequisite to apoptosis. Proc Natl Acad SciUSA 97:9487-9492
38. Bortner CD, Hughes FM Jr, Cidlowski JA (1997) A primary rolefor K? and Na? efflux in the activation of apoptosis. J Biol Chem272:32436-32442
39. Bortner CD, Cidlowski JA (1999) Caspase independent/dependentregulation of K?, cell shrinkage, and mitochondrial membranepotential during lymphocyte apoptosis. J Biol Chem274:21953-21962
40. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD (1997)The release of cytochrome c from mitochondria: a primary sitefor Bcl-2 regulation of apoptosis. Science 275:1132-1136
41. He H, Lam M, McCormick TS, Distelhorst CW (1997) Maintenanceof calcium homeostasis in the endoplasmic reticulum byBcl-2. J Cell Biol 138:1219-1228
42. Kirchengast M, Munter K (1999) Endothelin-1 and endothelinreceptor antagonists in cardiovascular remodeling. Proc Soc ExpBiol Med 221:312-325
43. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G,Kalachikov S, Cayanis E, Fischer SG, Barst RJ, Hodge SE,Knowles JA (2000) Familial primary PAH (gene PPH1) is causedby mutations in the bone morphogenetic protein receptor-II gene.Am J Hum Genet 67:737-744
44. Gurbanov E, Shiliang X (2006) The key role of apoptosis in thepathogenesis and treatment of PAH. Eur J Cardiothorac Surg30:499-507
45. Gibbons GH, Dzau VJ (1994) The emerging concept of vascularremodeling. N Engl J Med 330:1431-1438
46. Cowan KN, Heilbut A, Humpl T, Lam C, Ito S, Rabinovitch M(2000) Complete reversal of fatal PAH in rats by a serine elastaseinhibitor. Nat Med 6:698-702
47. Cowan KN, Jones PL, Rabinovitch M (1999) Regression ofhypertrophied rat pulmonary arteries in organ culture is associatedwith suppression of proteolytic activity, inhibition of tenascin-C, and smooth muscle cell apoptosis. Circ Res 84:1223-1233
48. Stenmark KR, Fagan KA, Frid MG (2006) Hypoxia-inducedpulmonary vascular remodeling: cellular and molecular mechanisms.Circ Res 99:675-691
49. Rai PR, Cool CD, King JA, Stevens T, Burns N, Winn RA,Kasper M, Voelkel NF (2008) The cancer paradigm of severepulmonary arterial hypertension. Am J Respir Crit Care Med178(6):558-564
50. Ali O, Wharton J, Gibbs JS, Howard L, Wilkins MR (2007)Emerging therapies for pulmonary arterial hypertension. ExpertOpin Investig Drugs 16:803-818
51. Weigand L, Sylvester J, Shimoda L (2006) Mechanisms ofendothelin-1- induced contraction in pulmonary arteries fromchronically hypoxic rats. Am J Physiol Lung Cell Mol Physiol290:L284-L290
52. Barman S (2007) Vasoconstrictor effect of endothelin-1 onhypertensive pulmonary arterial smooth muscle involves Rhokinase and protein kinase C. Am J Physiol Lung Cell Mol Physiol293:L472-L479
53. Liu Y, Suzuki Y, Day R, Fanburg BL (2004) Rho kinase-inducednuclear translocation of ERK1/ERK2 in smooth muscle cellmitogenesis caused by serotonin. Circ Res 95:579-586
54. Li M, Liu Y, Dutt P, Fanburg B, Toksoz D (2007) Inhibition ofserotonin-induced mitogenesis, migration, and ERK MAPKnuclear translocation in vascular smooth muscle cells by atorvastatin.Am J Physiol Lung Cell Mol Physiol 293:L463-L471
55. Takemoto M, Sun J, Hiroki J, Shimokawa H, Liao JK (2002)Rho-kinase mediates hypoxia-induced downregulation of endothelialnitric oxide synthase. Circulation 106:57-62
56. Nagaoka T, Morio Y, Casanova N, Bauer N, Gebb S, McMurtryI, Oka M (2004) Rho/Rho kinase signaling mediates increasedbasal pulmonary vascular tone in chronically hypoxic rats. Am JPhysiol Lung Cell Mol Physiol 287:L665-L672
57. Oka M, Homma N, Taraseviciene-Stewart L, Morris KG,Kraskauskas D, Burns N, Voelkel NF, McMurtry IF (2007) Rhokinase-mediated vasoconstriction is important in severe occlusivepulmonary arterial hypertension in rats. Circ Res 100:923-929
58. Fagan K, Oka M, Bauer NR, Gebb SA, Ivy DD, Morris KG,McMurtry IF (2004) Attenuation of acute hypoxic pulmonaryvasoconstriction and hypoxic PAH in mice by inhibition of Rhokinase.Am J Physiol Lung Cell Mol Physiol 287:L656-L664
59. Abe K, Shimokawa H, Morikawa K, Uwatoku T, Oi K, MatsumotoY, Hattori T, Nakashima Y, Kaibuchi K, Sueishi K,Takeshit A (2004) Long-term treatment with a Rho-kinaseinhibitor improves monocrotaline-induced fatal PAH in rats. CircRes 94:385-393
60. Abe K, Tawara S, Oi K, Hizume T, Uwatoku T, Fukumoto Y,Kaibuchi K, Shimokawa H (2006) Long term inhibition of Rhokinaseameliorates hypoxia-induced PAH in mice. J CardiovascPharmacol 48:280-285
61. Jiang B, Tawara S, Abe K, Takaki A, Fukumoto Y, Shimokawa H(2007) Acute vasodilator effect of fasudil, a Rho-kinase inhibitor,in monocrotaline-induced PAH in rats. J Cardiovasc Pharmacol49:85-89
62. Li F, Xia W, Li A, Zhao CF, Sun RP (2007) Inhibition of rhokinase attenuates high flow induced PAH in rats. Chin Med J120:22-29
63. Li F, Xia W, Li A, Zhao CF, Sun RP (2007) Long-term inhibitionof Rho kinase with fasudil attenuates high flow induced pulmonaryartery remodeling in rats. Pharmacol Res 55:64-71 (Pubitemid 46108589)
64. Fukumoto Y, Matoba T, Ito A, Tanaka H, Kishi T, HayashidaniS, Abe K, Takeshita A, Shimokawa H (2005) Acute vasodilatoreffects of a Rho-kinase inhibitor, fasudil, in patients with severePAH. Heart 91:391-392
65. Ishikura K, Yamada N, Ito M, Ota S, Nakamura M, Isaka N,Nakano T (2006) Beneficial acute effects of rho-kinase inhibitorin patients with pulmonary arterial hypertension. Circ J 70:174-178
66. Nishimura T, Faul J, Berry G, Vaszar LT, Qiu D, Pearl RG, KaoPN (2002) Simvastatin attenuates smooth muscle neointimalproliferation and PAH in rats. Am J Respir Crit Care Med166:1403-1408
67. Hu H, Sung A, Zhao G, Shi L, Qiu D, Nishimura T, Kao PN(2006) Simvastatin enhances bone morphogenetic proteinreceptor type II expression. Biochem Biophys Res Commun339:59-64
68. Shi J, Wei L (2007) Rho kinase in the regulation of cell death andsurvival. Arch Immunol Ther Exp 55:61-75
69. Shibata R, Kai H, Seki Y, Kusaba K, Takemiya K, Koga M,Jalalidin A, Tokuda K, Tahara N, Niiyama H, Nagata T, KuwaharaF, Imaizumi T (2003) Rho-kinase inhibition reduces neointimaformation after vascular injury by enhancing Baxexpression and apoptosis. J Cardiovasc Pharmacol 42(Suppl1):S43-S47
70. Matsumoto Y, Uwatoku T, Oi K, Abe K, Hattori T, Morishige K,Eto Y, Fukumoto Y, Nakamura K, Shibata Y, Matsuda T,Takeshita A, Shimokawa H (2004) Long-term inhibition of Rhokinasesuppresses neointimal formation after stent implantation inporcine coronary arteries: involvement of multiple mechanisms.Arterioscler Thromb Vasc Biol 24:181-186
71. Shibuya M, Hirai S, Seto M, Satoh S, Ohtomo E, FasudilIschemic Stroke Study Group (2005) Effects of fasudil in acuteischemic stroke: results of a prospective placebo-controlleddouble-blind trial. J Neurol Sci 238(1-2):31-39
72. Furuyama T, Komori K, Shimokawa H, Matsumoto Y, UwatokuT, Hirano K, Maehara Y (2006) Long-term inhibition of Rhokinase suppresses intimal thickening in autologous vein grafts inrabbits. J Vasc Surg 43:1249-1256
73. Nishimura T, Vaszar LT, Faul JL, Zhao G, Berry GJ, Shi L, QiuD, Benson G, Pearl RG, Kao PN (2003) Simvastatin rescues ratsfrom fatal PAH by inducing apoptosis of neointimal smoothmuscle cells. Circulation 108:1640
74. Laufs U, Marra D, Node K, Liao JK (1999) 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascularsmooth muscle proliferation preventing rho GTPase-induceddown-regulation of p27 (Kip 1). J Biol Chem 274:21926-21931
75. Indolfi C, Cioppa A, Stabile E, Di Lorenzo E, Esposito G, PisaniA, Leccia A, Cavuto L, Stingone AM, Chieffo A, Capozzolo C,Chiariello M (2000) Effects of hydroxymethylglutaryl coenzymeA reductase inhibitor simvastatin on smooth muscle cell proliferationin vitro and neointimal formation in vivo after vascularinjury. J Am Coll Cardiol 35:214-221
76. Tobert JA (1987) New developments in lipid-lowering therapy:the role of inhibitors of hydroxymethylglutaryl-coenzyme Areductase. Circulation 76:534-538
77. Michelakis ED, McMurtry MS, Wu XC, Dyck JR, Moudgil R,Hopkins TA, Lopaschuk GD, Puttagunta L, Waite R, Archer SL(2002) Dichloroacetate, a metabolic modulator, prevents andreverses chronic hypoxic PAH in rats: role of increased expressionand activity of voltage-gated potassium channels. Circulation105:244-250
78. McMurtry MS, Bonnet S, Wu X, Dyck JR, Haromy A, HashimotoK, Michelakis ED (2004) Dichloroacetate prevents andreverses PAH by inducing pulmonary artery smooth muscle cellapoptosis. Circ Res 95:830-840
79. Stacpoole PW, Kerr DS, Barnes C, Bunch ST, Carney PR, FennellEM, Felitsyn NM, Gilmore RL, Greer M, Henderson GN,Hutson AD, Neiberger RE, O'Brien RG, Perkins LA, QuislingRG, Shroads AL, Shuster JJ, Silverstein JH, Theriaque DW,Valenstein E (2006) Controlled clinical trial of dichloroacetatefor treatment of congenital lactic acidosis in children. Pediatrics117:1519-1531
80. Liu H, Nishitoh H, Ichijo H, Kyriakis JM (2000) Activation ofapoptosis signal-regulating kinase 1 (ASK1) by tumor necrosisfactor receptorassociated factor 2 requires prior dissociation ofthe ASK1 inhibitor thioredoxin. Mol Cell Biol 20:2198-2208
81. Tobiume K, Matsuzawa A, Takahashi T, Nishitoh H, Morita K,Takeda K, Minowa O, Miyazono K, Noda T, Ichijo H (2002)ASK1 is required for sustained activations of JNK/p38 MAPkinases and apoptosis. EMBO J 2:222-228
82. Izumi Y, Kim S, Yoshiyama M, Izumiya Y, Yoshida K, MatsuzawaA, Koyama H, Nishizawa Y, Ichijo H, Yoshikawa J,Iwao H (2003) Activation of apoptosis signal-regulating kinase 1in injured artery and its critical role in neointimal hyperplasia.Circulation 108:2812-2818
83. Hart CM (2008) The role of PPARgamma in pulmonary vasculardisease. J Investig Med 56:518-521
84. Ameshima S, Golpon H, Cool CD, Chan D, Vandivier RW,Gardai SJ, Wick M, Nemenoff RA, Geraci MW, Voelkel NF(2003) Peroxisome proliferator-activated receptor gamma(PPARgamma) expression is decreased in PAH and affectsendothelial cell growth. Circ Res 92:1162-1169
85. Matsuda Y, Hoshikawa Y, Ameshima S, Suzuki S, Okada Y,Tabata T, Sugawara T, Matsumura Y, Kondo T (2005) Effects ofperoxisome proliferator-activated receptor gamma ligands onmonocrotaline-induced PAH in rats. Nihon Kokyuki GakkaiZasshi 43:283-288
86. Crossno JT Jr, Garat CV, Reusch JE, Morris KG, Dempsey EC,McMurtry IF, Stenmark KR, Klemm DJ (2007) Rosiglitazoneattenuates hypoxia-induced pulmonary arterial remodeling. Am JPhysiol Lung Cell Mol Physiol 292:L885-L897
87. Nisbet R, Kleinhenz D, Thorson H et al (2007) Rosiglitazoneattenuates chronic hypoxia-induced PAH. Am J Respir Crit CareMed 175:A43
88. Calnek DS, Mazzella L, Roser S, Roman J, Hart CM (2003)Peroxisome proliferator-activated receptor gamma ligandsincrease release of nitric oxide from endothelial cells. ArteriosclerThromb Vasc Biol 23:52-57
89. Polikandriotis JA, Mazzella LJ, Rupnow HL, Hart CM (2005)Peroxisome proliferator-activated receptor gamma ligands stimulateendothelial nitric oxide production through distinct peroxisomeproliferator-activated receptor gamma-dependentmechanisms. Arterioscler Thromb Vasc Biol 25:1810-1816
90. Hwang J, Kleinhenz DJ, Lassegue B, Griendling KK, Dikalov S,Hart CM (2005) Peroxisome proliferator-activated receptorgammaligands regulate endothelial membrane superoxide production.Am J Physiol Cell Physiol 288:C899-C905
91. Hwang J, Kleinhenz DJ, Rupnow HL, Campbell AG, Thulé PM,Sutliff RL, Hart CM (2007) The PPAR gamma ligand, rosiglitazone,reduces vascular oxidative stress and NADPH oxidaseexpression in diabetic mice. Vascul Pharmacol 46:456-462
92. Singh S, Loke YK (2008) The safety of rosiglitazone in thetreatment of type 2 diabetes. Expert Opin Drug Saf 7(5):579-585
93. Taraseviciene-Stewart L, Scerbavicius R, Stewart JM, Gera L,Demura Y, Cool C, Kasper M, Voelkel NF (2005) Treatment ofsevere PAH: a bradykinin receptor 2 agonist B9972 causesreduction of pulmonary artery pressure and right ventricularhypertrophy. Peptides 26:1292-1300
94. Heitsch H (2000) Bradykinin B2 receptor as a potential therapeutictarget. Drug News Perspect 13:213-225
95. Merklinger SL, Jones PL, Martinez EC, Rabinovitch M (2005)Epidermal growth factor receptor blockade mediates smoothmuscle cell apoptosis and improves survival in rats with PAH.Circulation 112:423-431
96. Blanc-Brude OP, Yu J, Simosa H, Conte MS, Sessa WC, AltieriDC (2002) Inhibitor of apoptosis protein survivin regulates vascularinjury. Nat Med 8(9):987-994
97. Altieri DC (2003) Validating survivin as a cancer therapeutictarget. Nat Rev Cancer 3(1):46-54
98. Mita AC, Mita MM, Nawrocki ST, Giles FJ (2008) Survivin: keyregulator of mitosis and apoptosis and novel target for cancertherapeutics. Clin Cancer Res 14(16):5000-5005